/
Oncology
Breast Cancer
789
Pipeline Programs↗
2.0K
Active Trials↗
377
Companies Involved↗
Breast Cancer is a highly competitive landscape with 789 programs across 377 companies. The most active players are Sichuan Baili Pharmaceutical Co., Ltd., AstraZeneca, Roche. 186 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical209
Phase 188
Phase 2306
Phase 3186
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
616 of 715 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 715 classified programs, each share of the total. Modality classified for 94% of 789 pipeline programs.
Analysis
Trial Status
6,242
clinical trials
Completed2,584 · 41%
Recruiting1,027 · 16%
Unknown status709 · 11%
Terminated659 · 11%
Active, not recruiting596 · 10%
Not yet recruiting400 · 6%
Other267 · 4%
Clinical Trials
Trial Activity
6242 trials
Page 1 of 417
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)